Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Trevena Inc (TRVN)

Trevena Inc (TRVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,397
  • Shares Outstanding, K 864
  • Annual Sales, $ 3,130 K
  • Annual Income, $ -40,290 K
  • EBIT $ -32 M
  • EBITDA $ -32 M
  • 60-Month Beta 1.08
  • Price/Sales 0.44
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -47.04
  • Most Recent Earnings $-5.79 on 11/07/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 94.34%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -2.50
  • Number of Estimates 1
  • High Estimate -2.50
  • Low Estimate -2.50
  • Prior Year -26.50
  • Growth Rate Est. (year over year) +90.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3096 +21.41%
on 12/05/24
2.1900 -27.40%
on 11/13/24
-0.4300 (-21.29%)
since 11/11/24
3-Month
1.1300 +40.71%
on 10/08/24
7.5192 -78.85%
on 09/12/24
-5.9000 (-78.77%)
since 09/11/24
52-Week
1.1300 +40.71%
on 10/08/24
19.2325 -91.73%
on 01/10/24
-13.8600 (-89.71%)
since 12/11/23

Most Recent Stories

More News
Trevena: Q3 Earnings Snapshot

Trevena: Q3 Earnings Snapshot

TRVN : 1.5900 (-1.70%)
Trevena Reports Third Quarter 2024 Results and Provides Business Update

TRVN : 1.5900 (-1.70%)
Trevena Announces Receipt of Nasdaq Delisting Notification

TRVN : 1.5900 (-1.70%)
Trevena: Q2 Earnings Snapshot

Trevena: Q2 Earnings Snapshot

TRVN : 1.5900 (-1.70%)
Trevena: Q1 Earnings Snapshot

Trevena: Q1 Earnings Snapshot

TRVN : 1.5900 (-1.70%)
Trevena: Q4 Earnings Snapshot

Trevena: Q4 Earnings Snapshot

TRVN : 1.5900 (-1.70%)
Trevena: Q3 Earnings Snapshot

Trevena: Q3 Earnings Snapshot

TRVN : 1.5900 (-1.70%)
Trevena: Q2 Earnings Snapshot

Trevena: Q2 Earnings Snapshot

TRVN : 1.5900 (-1.70%)
Trevena: Q1 Earnings Snapshot

Trevena: Q1 Earnings Snapshot

TRVN : 1.5900 (-1.70%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.084 (+2.44%)
SILO : 0.9496 (+1.02%)
LLY : 796.03 (-0.44%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.5900 (-1.70%)
IMRN : 2.24 (+11.24%)

Business Summary

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of...

See More

Key Turning Points

3rd Resistance Point 1.6833
2nd Resistance Point 1.6367
1st Resistance Point 1.6133
Last Price 1.5900
1st Support Level 1.5433
2nd Support Level 1.4967
3rd Support Level 1.4733

See More

52-Week High 19.2325
Fibonacci 61.8% 12.3173
Fibonacci 50% 10.1812
Fibonacci 38.2% 8.0452
Last Price 1.5900
52-Week Low 1.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar